Diversity in Renal Function Monitoring and Dose Modifications During Treatment for Childhood Cancer: A Call for Standardization

被引：5
|
作者：
Blufpand, Hester N. [1 ]
Hes, Nicole [1 ]
Bokenkamp, Arend [1 ]
van de Wetering, Marianne D. [2 ]
Kaspers, Gertjan J. L. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands
[2] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands
来源：
PEDIATRIC BLOOD & CANCER | 2014年 / 61卷 / 02期
关键词：
adverse effects; chemotherapy induced nephrotoxicity; childhood cancer; dose modifications in case of renal dysfunction; renal function; IFOSFAMIDE-INDUCED NEPHROTOXICITY; GLOMERULAR-FILTRATION-RATE; CYSTATIN-C; SERUM CREATININE; SARCOMA PATIENTS; KIDNEY-FUNCTION; RISK-FACTORS; CHILDREN; SURVIVORS; CARBOPLATIN;
D O I：
10.1002/pbc.24572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite changes in survival and drug tolerability, nephrotoxicity remains an important complication of chemotherapy. To provide cutting-edge care for children with cancer oncologist must be familiar with their nephrotoxic potential. Careful monitoring of renal function during treatment is therefore indicated. Well-defined guidelines for this are lacking. We reviewed current DCOG protocols and showed that monitoring of renal function during treatment varies widely between protocols. In some protocols recommended renal function measures are inappropriate given the chemotherapy prescribed. Advices on dose modifications in case of renal dysfunction also vary, even with comparable regimens. These differences are unwanted and call for standardization. Pediatr Blood Cancer 2014;61:337-344. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码：337 / 344
页数：8
相关论文
共 50 条
  • [31] Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment
    Svensson, Johanna
    Berg, Gertrud
    Wangberg, Bo
    Larsson, Maria
    Forssell-Aronsson, Eva
    Bernhardt, Peter
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (06) : 947 - 955
  • [32] INVESTIGATING RENAL-FUNCTION DURING LITHIUM TREATMENT
    WALLER, DG
    EDWARDS, JG
    PSYCHOLOGICAL MEDICINE, 1985, 15 (02) : 369 - 375
  • [33] RENAL-FUNCTION CHANGES DURING TREATMENT WITH CISPLATIN
    OFFERMAN, JJG
    MEIJER, S
    SLEIJFER, DT
    MULDER, NH
    DONKER, AJM
    KOOPS, HS
    VANDERHEM, GK
    KIDNEY INTERNATIONAL, 1984, 26 (03) : 368 - 369
  • [34] RENAL-FUNCTION OF NEONATES DURING GENTAMICIN TREATMENT
    TESSIN, I
    BERGMARK, J
    HIESCHE, K
    JAGENBURG, R
    TROLLFORS, B
    ARCHIVES OF DISEASE IN CHILDHOOD, 1982, 57 (10) : 758 - 760
  • [35] Is liver function monitoring warranted during risperidone treatment?
    Landau, JE
    Martin, A
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1998, 37 (10): : 1007 - 1008
  • [36] INVESTIGATION OF RENAL TUBULAR FUNCTION DURING TREATMENT WITH LITHIUM
    WALLER, DG
    EDWARDS, JG
    NEUROPHARMACOLOGY, 1984, 23 (2B) : 277 - 279
  • [37] IMPACT OF SCHOOL HOSPITAL DURING THE TREATMENT OF CHILDHOOD CANCER
    Gazaui, Mildred
    Espino, Sonia
    Briceno, Rosa
    Pereira, Augusto
    Hernandez, Adelina
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 870 - 870
  • [38] HIGH-DOSE INTRAVENOUS IGG TREATMENT AND RENAL-FUNCTION
    SCHIFFERLI, J
    LESKI, M
    FAVRE, H
    IMBACH, P
    NYDEGGER, U
    DAVIES, K
    LANCET, 1991, 337 (8739): : 457 - 458
  • [39] Sexual function after treatment for sacrococcygeal teratoma during childhood
    Kremer, Marijke E. B.
    Derikx, Joep P. M.
    Peeters, Andrea
    ter Kuile, Moniek M.
    van Baren, Robertine
    Heij, Hugo A.
    Wijnen, Marc H. W. A.
    Wijnen, Rene M. H.
    van der Zee, David C.
    van Heurn, L. W. Ernest
    JOURNAL OF PEDIATRIC SURGERY, 2016, 51 (04) : 534 - 540
  • [40] Integrative assessment of the effect of renal function on ribociclib treatment and dose recommendation in advanced breast cancer patients.
    Ji, Yan
    Yartsev, Vitaly
    Wang, Yingbo
    Quinlan, Michelle
    Serra, Paolo
    Samant, Tanay
    Rodriguez-Lorenc, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345